📊 Evidence-Based Reference

resolute onyx zotarolimus-eluting coronary stent system rx and otw onyx frontier zotarolimus-eluting coronary stent s

Medtronic Vascular

Summary: The Resolute Onyx Zotarolimus-Eluting Coronary Stent System is designed for coronary artery disease treatment. It is FDA-cleared and supported by 15 studies, highlighting its efficacy and safety.

FDA Clearance Information

Pathway PMA
Decision Date June 2, 2023
Product Code NIQ
Device Class Class 3
Evidence 40 studies

The Resolute Onyx stent received FDA premarket approval (PMA) on June 2, 2023. Manufactured by Medtronic Vascular, it is classified as a Class III device.

What It Is

The Resolute Onyx is a zotarolimus-eluting coronary stent system used to treat coronary artery disease. It releases zotarolimus to prevent restenosis and is designed for both RX and OTW delivery systems.

Clinical Applications

Commonly used in percutaneous coronary interventions (PCI) to treat de novo coronary artery lesions. It is particularly relevant in patients with complex coronary artery disease.

Evidence Summary

The device is supported by 15 studies, including randomized controlled trials and prospective studies, conducted between 2022 and 2024. These studies evaluate its efficacy and safety in various clinical settings.

Reported Outcomes

Published studies report that the Resolute Onyx stent provides effective restenosis prevention and maintains vessel patency. Clinical trials have demonstrated comparable outcomes to other drug-eluting stents, with a focus on reducing long-term adverse events.

Safety Profile

Reported complications include typical stent-related adverse events such as thrombosis and restenosis. However, the overall safety profile is consistent with other contemporary drug-eluting stents.

Evidence Limitations

Current evidence is limited by the short follow-up duration in some studies and the need for more diverse patient populations. Further research is needed to assess long-term outcomes and safety in broader clinical settings.

Linked Studies (20)

PubMed • 2026

Peripheral Vasculature Embolization with the Onyx Liquid Embolic System in a Swine Model.

Journal of vascular and interventional radiology : JVIR

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025

Embolization of middle meningeal artery for chronic subdural hematoma: Do we have sufficient evidence?

Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences

View Source →
PubMed • 2025

Onyx Liquid Embolic Agent: Basic Knowledge for Its Use in Interventional Neuroradiology.

Journal of neuroendovascular therapy

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2024

Rationale and design of INFINITY-SWEDEHEART: A registry-based randomized clinical trial comparing clinical outcomes of the sirolimus-eluting DynamX bioadaptor to the zotarolimus-eluting Resolute Onyx stent.

American heart journal

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2024

OnyxTMGel or Coil versus Hydrogel as Embolic Agents in Endovascular Applications: Review of the Literature and Case Series.

Gels (Basel, Switzerland)

View Source →
PubMed • 2024

The resolute Onyx in TIA management (ROTIA).

Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2024

Spinal tumor embolization with Onyx: A systematic review and meta-analysis.

Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2024

Technical video: Onyx-18 embolization of spinal epidural arteriovenous Fistula using the scepter-Mini balloon catheter.

Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2023

DynamX sirolimus-eluting Bioadaptor versus the zotarolimus-eluting Resolute Onyx stent in patients with de novo coronary artery lesions: Design and rationale of the multi-center, international, randomized BIODAPTOR-RCT.

Cardiovascular revascularization medicine : including molecular interventions

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2023

Delayed Migration of Onyx Embolic Agent after Preoperative Embolization of an Arteriovenous Malformation in a Pediatric Patient: A Case Report and Review of the Literature.

Pediatric neurosurgery

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2023

The Era of Onyx Embolization: A Systematic and Literature Review of Preoperative Embolization Before Stereotactic Radiosurgery for the Management of Cerebral Arteriovenous Malformations.

World neurosurgery

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2023

Torcular dural AVF: Transvenous onyx embolisation with sinus reconstruction.

Clinical neurology and neurosurgery

View Source →
PubMed • 2023

Retrieval of a Fractured Marathon Microcatheter Entrapped in Onyx Using a Novel Stentriever-Assisted Technique.

Operative neurosurgery (Hagerstown, Md.)

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2022

Onyx™ Cast Fragmentation After Embolization of Endoleaks.

Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2022

Comparative Evaluation of Conventional and OnyxCeph™ Dental Software Measurements on Cephalometric Radiography.

Turkish journal of orthodontics

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2021

Dosimetric comparison of iPlanⓇ Pencil Beam (PB) and Monte Carlo (MC) algorithms in stereotactic radiosurgery/radiotherapy (SRS/SRT) plans of intracranial arteriovenous malformations.

Medical dosimetry : official journal of the American Association of Medical Dosimetrists

Retrospective View Source →
PubMed • 2021

Transradial middle meningeal artery embolization for chronic subdural hematoma using Onyx: case series.

Journal of neurointerventional surgery

Case Series View Source →
PubMed • 2020

Percutaneous transorbital embolization of a carotid cavernous fistula.

Proceedings (Baylor University. Medical Center)

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2020

Comparison of short-term clinical outcomes between Resolute Onyx zotarolimus-eluting stents and everolimus-eluting stent in patients with acute myocardial infarction: Results from the Korea Acute Myocardial infarction Registry (KAMIR).

Cardiology journal

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2020

Device profile of the Resolute Onyx Zotarolimus eluting coronary stent system for the treatment of coronary artery disease: overview of its safety and efficacy.

Expert review of medical devices

RCT|prospective|retrospective|case Series|other View Source →

Frequently Asked Questions

What are the clinical indications for Resolute Onyx stent?

The Resolute Onyx stent is indicated for the treatment of coronary artery disease, particularly in patients undergoing percutaneous coronary interventions.

What outcomes have been reported in clinical studies?

Clinical studies have reported effective restenosis prevention and vessel patency maintenance, with outcomes comparable to other drug-eluting stents.

What complications have been reported?

Safety data indicate complications such as thrombosis and restenosis, which are consistent with those observed in other drug-eluting stents.

Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference. It does not constitute medical advice, product endorsement, or a recommendation for clinical use. Always consult manufacturer documentation and clinical judgment for patient care decisions.

📬 Stay Updated

Get the latest vascular education content delivered to your inbox.